Table 1.
Comparison between the screened and the final study cohort
| Final study cohort N = 148 | Screened cohort N = 446 | p-value | |
|---|---|---|---|
| Gender [Male %f] | 105 (70.9%) | 312 (70.0%) | P = 0.82 |
| Median age at initial diagnose [in years] | 33.5 (26–47) | 32 (24–44) | P = 0.21 |
| Median time of follow-up [in years] | 9 (3–14) | 9 (4–14) | P = 0.91 |
| Patients diagnosed with AIH/PSC overlap | 9 (6.1%) | 29 (6.6%) | P = 0.82 |
| Presence of dominant stenosis | 87 (58.8%) | 268 (60.6%) | P = 0.72 |
| Presence of IBD | 99 (66.9%) | 315 (70.9%) | P = 0.42 |
| BMI | 22.7 (17.1–31.9) | 22.7 (17.3–56.7) | P = 0.5 |
| Mayo Risk Score (MRS) | −0.2 (−3.1–2.3) | −0.1 (− 2.7–2.8) | P = 0.8 |
| OLT | 32 (21.6%) | 107 (30.4%) | P = 0.042 |
| Re-OLT | 9 (6.1%) | 21 (6%) | P = 1.02 |
| Death | 37 (25%) | 66 (18.8%) | P = 0.22 |
| Combined end-point (OLT and death) | 57 (38.5%) | 144 (40.9%) | P = 0.62 |
| CCA | 12 (8.1%) | 31 (8.8%) | P = 0.82 |
1Mann-Witney- U test was applied
2Chi2-Test was applied
Abbreviation: AIH/PSC = autoimmune hepatitis/primary sclerosing cholangitis, CCA = cholangiocarcinoma, IBD = Inflammatory bowel disease, MRS = Mayo Risk ScoreOLT = orthotopic liver transplantation